Bone mineral density in patients with atopic dermatitis

Chemical Immunology and Allergy

Volumn 96, Issue , 2012, Pages 96-99

  Haeck, Inge ^a   Van Velsen, Sara ^a   De Bruin Weller, Marjolein ^a   Bruijnzeel Koomen, Carla ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CORTICOSTEROID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; VITAMIN D;

ARTICLE; ATOPIC DERMATITIS; BONE DENSITY; CHRONIC INFLAMMATION; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG USE; FOLLOW UP; HUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN SUPPLEMENTATION; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFECT; FRACTURE; NETHERLANDS; PRACTICE GUIDELINE; RISK FACTOR; RISK REDUCTION; UNITED KINGDOM; UNITED STATES; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

BONE DENSITY; CALCIUM; DERMATITIS, ATOPIC; DIETARY SUPPLEMENTS; FOLLOW-UP STUDIES; HUMANS; MALE; VITAMIN D;

EID: 84859187800     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000331893     Document Type: Article

References (22)

1. Haeck I, Hamdy N, Timmer-de Mik, L, Lentjes E, Verhaar H, Knol M, de Bruin-Weller M, Bruijnzeel-Koomen C: Low bone mineral density in adult patients with moderate to severe atopic dermatitis. Br J Dermatol 2009;161:1248-1254.
2. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K: Osteoporosis: An age-related and genderspecific disease-a mini-review. Gerontology 2009; 55:3-12.
3. Aalto-Korte K, Turpeinen M: Bone mineral density in patients with atopic dermatitis. Br J Dermatol 1997;136:172-175.
4. Munro DD: The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients. Br J Dermatol 1976;94(suppl 12):67-76.
5. Munro DD: Topical corticosteroid therapy and its effect on the hypothalamic-pituitary-adrenal axis. Dermatologica 1976;152(suppl 1):173-180.
6. Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, et al: Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol 1988;90:532-535.
7. Hehir M, Du VA, Eilon L, Danie MJ, Shenoy EV: Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol 1983;8: 143-151.
8. Pariser D: Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: Focus on percutaneous absorption. Am J Ther 2009;16:264-273.
9. van Velsen S, Haeck I, Knol M, Lam M, Bruijnzeel-Koomen C: Two-year follow-up of bone mineral density in adults with moderate to severe atopic dermatitis: No effect of topical cortcosteroids. J Am Acad Dermatol 2010;63:824-831.
10. Farmacotherapeutisch Kompas 2009 The Netherlands. http://www. farmacotherapeutischkompas.nl (accessed December 2009).
11. Zuberbier T, Orlow SJ, Paller AS, Taieb A, Allen R, Hernanz-Hermosa JM, et al: Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006;118:226-232.
12. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-968.
13. Rizzato G, Montemurro L: Reversibility of exogenous corticosteroid- induced bone loss. Eur Respir J 1993;6:116-119.
14. LoCascio V, Ballanti P, Milani S, Bertoldo F, LoCascio C, Zanolin EM, et al: A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: Prednisone versus deflazacort. Calcif Tissue Int 1998;62:199-204.
15. Saito JK, Davis JW, Wasnich RD, Ross PD: Users of low-dose glucocorticoids have increased bone loss rates: A longitudinal study. Calcif Tissue Int 1995;57: 115-119.
16. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-293.
17. Walsh NC, Crotti TN, Goldring SR, Gravallese EM: Rheumatic diseases: The effects of inflammation on bone. Immunol Rev 2005;208:228-251.
18. Clowes JA, Riggs BL, Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005;208:207-227.
19. Isenor JE, Ensom MH: Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk? Pharmacotherapy 2010;30: 254-264.
20. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebocontrolled trial. Ann Intern Med 1996;125:961-968.
21. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, et al: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year follow-up. J Rheumatol 1996; 23:995-1000.
22. Compston J: Management of glucocorticoidinduced osteoporosis. Nat Rev Rheumatol 2010;6: 82-88.